Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema
AACE Endocrinology and Diabetes
· Elsevier
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Читать у издателя →
Цитирование
Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema. // AACE Endocrinology and Diabetes. – URL: https://www.sciencedirect.com/science/article/pii/S3050915726000743?dgcid=rss_sd_all
Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema. AACE Endocrinology and Diabetes. https://www.sciencedirect.com/science/article/pii/S3050915726000743?dgcid=rss_sd_all
“Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema.” AACE Endocrinology and Diabetes.
@article{article99537,
title = {Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema},
journal = {AACE Endocrinology and Diabetes},
url = {https://www.sciencedirect.com/science/article/pii/S3050915726000743?dgcid=rss_sd_all}
}